• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

绝经期女性咨询:如何权衡绝经激素治疗的利弊。FIGO 立场文件。

Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper.

机构信息

Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, The University of Pisa, Pisa, Italy.

Obstetrics and Gynaecology, Divakars Speciality Hospital, Bengaluru, India.

出版信息

Int J Gynaecol Obstet. 2024 Feb;164(2):516-530. doi: 10.1002/ijgo.15278. Epub 2024 Jan 4.

DOI:10.1002/ijgo.15278
PMID:38178609
Abstract

Menopause marks the end of menstrual cyclicity and, depending on individual vulnerability, has several consequences related to gonadal steroid deprivation, especially if it is premature. Menopause may be more burdensome for some women than for others. Individual factors, such as personal history, socioeconomic status, ethnicity, and current health conditions, affect symptomatology and, thereby, the menopausal experience. In addition, some menopausal symptoms, such as severe hot flashes, sleep disorders, and depression, are markers of future health risks. Counseling is a fundamental part of health care in the peri- and postmenopause periods. It must include an assessment of the patient's symptoms, needs, desires, and risk profile to address the benefits and risks of menopausal hormone therapy (MHT) on an individual basis and promote a healthy lifestyle. Indeed, healthcare practitioners can and must protect the health and lives of mid-life women by increasing awareness of menopausal symptoms and ensuring healthcare options, especially MHT. The type and duration of MHT should be tailored based on the patient's history, menopausal age, physical characteristics, and current health status so that the benefits always outweigh the risks. This FIGO position paper focuses on the benefits and risks of MHT on health domains, target organs, and systems, and on systemic and vaginal MHT regimens, to provide indications that can be used in the clinical practice for menopausal counseling. Moreover, it offers insights into what FIGO considers the mainstay for the healthcare management of women in peri- and postmenopause, worldwide.

摘要

绝经标志着月经周期的结束,并且取决于个体的脆弱性,它会带来与性腺类固醇缺乏有关的多种后果,尤其是如果绝经过早的话。对于一些女性来说,绝经可能比其他人更具负担。个人因素,如个人病史、社会经济地位、种族和当前健康状况,会影响症状表现,从而影响绝经体验。此外,一些绝经症状,如严重的热潮红、睡眠障碍和抑郁,是未来健康风险的标志物。咨询是围绝经期和绝经后期间保健的一个基本组成部分。它必须包括评估患者的症状、需求、愿望和风险概况,以根据个体情况解决绝经激素治疗 (MHT) 的益处和风险,并促进健康的生活方式。实际上,医疗保健从业者可以而且必须通过提高对绝经症状的认识并确保医疗保健选择,特别是 MHT,来保护中年女性的健康和生命。MHT 的类型和持续时间应根据患者的病史、绝经年龄、身体特征和当前健康状况进行调整,以便始终使益处大于风险。这份 FIGO 立场文件重点关注 MHT 对健康领域、靶器官和系统以及全身和阴道 MHT 方案的益处和风险,为绝经咨询提供可以在临床实践中使用的适应症。此外,它还深入探讨了 FIGO 认为是全球围绝经期和绝经后女性保健管理的主要内容。

相似文献

1
Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper.绝经期女性咨询:如何权衡绝经激素治疗的利弊。FIGO 立场文件。
Int J Gynaecol Obstet. 2024 Feb;164(2):516-530. doi: 10.1002/ijgo.15278. Epub 2024 Jan 4.
2
Hormone Therapy: Menopausal Hormone Therapy.激素治疗:绝经激素治疗。
FP Essent. 2023 Aug;531:15-21.
3
Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.绝经期后激素治疗:在临床实践中考虑获益与风险。
Hum Reprod Update. 2021 Oct 18;27(6):1115-1150. doi: 10.1093/humupd/dmab026.
4
Associations between menopausal hormone therapy and sleep disturbance in women during the menopausal transition and post-menopause: data from the Norwegian prescription database and the HUNT study.围绝经期和绝经后女性的绝经激素治疗与睡眠障碍的相关性:来自挪威处方数据库和 HUNT 研究的数据。
BMC Womens Health. 2020 Mar 30;20(1):64. doi: 10.1186/s12905-020-00916-8.
5
What the Women's Health Initiative has taught us about menopausal hormone therapy.妇女健康倡议组织关于绝经激素治疗给我们带来的启示。
Clin Cardiol. 2018 Feb;41(2):247-252. doi: 10.1002/clc.22891. Epub 2018 Mar 1.
6
Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group.绝经激素治疗(MHT)的适应证:医学状况女性使用 MHT 的科学学会联盟的立场声明。MHT 适应证标准制定组。
Maturitas. 2022 Dec;166:65-85. doi: 10.1016/j.maturitas.2022.08.008. Epub 2022 Aug 30.
7
Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens Français (CNGOF) and Groupe d'Etude sur la Ménopause et le Vieillissement (GEMVi) Clinical Practice Guidelines.绝经后女性管理:法国妇产科学院(CNGOF)和绝经与衰老研究小组(GEMVi)临床实践指南。
Maturitas. 2022 Sep;163:62-81. doi: 10.1016/j.maturitas.2022.05.008. Epub 2022 Jun 9.
8
Hormone therapy regimens for managing the menopause and premature ovarian insufficiency.激素治疗方案管理绝经和卵巢早衰。
Best Pract Res Clin Endocrinol Metab. 2021 Dec;35(6):101561. doi: 10.1016/j.beem.2021.101561. Epub 2021 Jun 30.
9
Persistent gap in menopause care 20 years after the WHI: a population-based study of menopause-related symptoms and their management.绝经后护理的持续差距:WHI 后 20 年的一项基于人群的绝经相关症状及其管理研究。
Maturitas. 2022 Dec;166:58-64. doi: 10.1016/j.maturitas.2022.08.003. Epub 2022 Aug 11.
10
Precision hormone therapy: identification of positive responders.精准激素治疗:阳性反应者的识别。
Climacteric. 2021 Aug;24(4):350-358. doi: 10.1080/13697137.2021.1882418. Epub 2021 Feb 22.